BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 11245553)

  • 1. A 1-year pharmacokinetic investigation of a novel oral contraceptive containing drospirenone in healthy female volunteers.
    Blode H; Wuttke W; Loock W; Röll G; Heithecker R
    Eur J Contracept Reprod Health Care; 2000 Dec; 5(4):256-64. PubMed ID: 11245553
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A pharmacokinetic study with a low-dose oral contraceptive containing 20 microg ethinylestradiol plus 100 microg levonorgestrel.
    Endrikat J; Blode H; Gerlinger C; Rosenbaum P; Kuhnz W
    Eur J Contracept Reprod Health Care; 2002 Jun; 7(2):79-90. PubMed ID: 12201326
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics of gestodene and ethinylestradiol in 14 women during three months of treatment with a new tri-step combination oral contraceptive: serum protein binding of gestodene and influence of treatment on free and total testosterone levels in the serum.
    Kuhnz W; Baumann A; Staks T; Dibbelt L; Knuppen R; Jütting G
    Contraception; 1993 Oct; 48(4):303-22. PubMed ID: 8222659
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transfer of drospirenone to breast milk after a single oral administration of 3 mg drospirenone + 30 microg ethinylestradiol to healthy lactating women.
    Blode H; Foidart JM; Heithecker R
    Eur J Contracept Reprod Health Care; 2001 Sep; 6(3):167-71. PubMed ID: 11763981
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drospirenone--a new progestogen with antimineralocorticoid activity, resembling natural progesterone.
    Oelkers W
    Eur J Contracept Reprod Health Care; 2000 Dec; 5 Suppl 3():17-24. PubMed ID: 11246598
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ethinylestradiol/drospirenone: a review of its use as an oral contraceptive.
    Keam SJ; Wagstaff AJ
    Treat Endocrinol; 2003; 2(1):49-70. PubMed ID: 15871554
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics of cyproterone acetate and ethinylestradiol in 15 women who received a combination oral contraceptive during three treatment cycles.
    Kuhnz W; Staks T; Jütting G
    Contraception; 1993 Dec; 48(6):557-75. PubMed ID: 8131397
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics of levonorgestrel and ethinylestradiol in 9 women who received a low-dose oral contraceptive over a treatment period of 3 months and, after a wash-out phase, a single oral administration of the same contraceptive formulation.
    Kuhnz W; al-Yacoub G; Fuhrmeister A
    Contraception; 1992 Nov; 46(5):455-69. PubMed ID: 1458892
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of two oral contraceptives containing ethinylestradiol and gestodene or norgestimate upon androgen parameters and serum binding proteins.
    Wiegratz I; Jung-Hoffmann C; Kuhl H
    Contraception; 1995 Jun; 51(6):341-6. PubMed ID: 7554973
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The acceptability of a novel oral contraceptive containing drospirenone and its effect on well-being.
    Boschitsch E; Skarabis H; Wuttke W; Heithecker R
    Eur J Contracept Reprod Health Care; 2000 Dec; 5 Suppl 3():34-40. PubMed ID: 11246600
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics of levonorgestrel and ethinylestradiol in 14 women during three months of treatment with a tri-step combination oral contraceptive: serum protein binding of levonorgestrel and influence of treatment on free and total testosterone levels in the serum.
    Kuhnz W; Staks T; Jütting G
    Contraception; 1994 Dec; 50(6):563-79. PubMed ID: 7705098
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A comparative investigation of contraceptive reliability, cycle control and tolerance of two monophasic oral contraceptives containing either drospirenone or desogestrel.
    Foidart JM; Wuttke W; Bouw GM; Gerlinger C; Heithecker R
    Eur J Contracept Reprod Health Care; 2000 Jun; 5(2):124-34. PubMed ID: 10943575
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of 2 combined oral Contraceptives containing either drospirenone or cyproterone acetate on acne and seborrhea.
    van Vloten WA; van Haselen CW; van Zuuren EJ; Gerlinger C; Heithecker R
    Cutis; 2002 Apr; 69(4 Suppl):2-15. PubMed ID: 12096825
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum pharmacokinetics of orally administered desogestrel and binding of contraceptive progestogens to sex hormone-binding globulin.
    Bergink W; Assendorp R; Kloosterboer L; van Lier W; Voortman G; Qvist I
    Am J Obstet Gynecol; 1990 Dec; 163(6 Pt 2):2132-7. PubMed ID: 2147817
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of an oral contraceptive containing drospirenone on the renin-angiotensin-aldosterone system in healthy female volunteers.
    Oelkers W; Helmerhorst FM; Wuttke W; Heithecker R
    Gynecol Endocrinol; 2000 Jun; 14(3):204-13. PubMed ID: 10923282
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomized study on the influence of oral contraceptives containing ethinylestradiol combined with drospirenone or desogestrel on lipid and lipoprotein metabolism over a period of 13 cycles.
    Gaspard U; Endrikat J; Desager JP; Buicu C; Gerlinger C; Heithecker R
    Contraception; 2004 Apr; 69(4):271-8. PubMed ID: 15033400
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The contraceptive profile of a new oral contraceptive with antimineralocorticoid and antiandrogenic effects.
    Foidart JM
    Eur J Contracept Reprod Health Care; 2000 Dec; 5 Suppl 3():25-33. PubMed ID: 11246599
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Experiences with Yasmin: the acceptability of a novel oral contraceptive and its effect on well-being.
    Mansour D
    Eur J Contracept Reprod Health Care; 2002 Dec; 7 Suppl 3():35-41; discussion 42-3. PubMed ID: 12659405
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and tolerability of a monophasic oral contraceptive containing ethinylestradiol and drospirenone.
    Huber J; Foidart JM; Wuttke W; Merki-Feld GS; The HS; Gerlinger C; Schellschmidt I; Heithecker R
    Eur J Contracept Reprod Health Care; 2000 Mar; 5(1):25-34. PubMed ID: 10836660
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Endocrine and metabolic effects of an oral contraceptive containing estetrol and drospirenone.
    Klipping C; Duijkers I; Mawet M; Maillard C; Bastidas A; Jost M; Foidart JM
    Contraception; 2021 Apr; 103(4):213-221. PubMed ID: 33428907
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.